MeSH term
Frequency | Condition_Probility | Animals | 154 | 0.0 |
Cell Line | 107 | 0.0 |
Cercopithecus aethiops | 4 | 0.0 |
Humans | 327 | 0.0 |
Protein Structure, Tertiary | 11 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 71 | 7.0 |
Recombinant Fusion Proteins/genetics/metabolism | 4 | 0.0 |
Research Support, Non-U.S. Gov't | 227 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 133 | 0.0 |
Subcellular Fractions/metabolism | 2 | 0.0 |
Cells, Cultured | 48 | 0.0 |
Interleukin-2/*pharmacology | 13 | 5.0 |
Lymphocyte Activation | 4 | 0.0 |
Microscopy, Confocal | 3 | 0.0 |
*Milk Proteins | 54 | 11.0 |
Phosphorylation | 148 | 1.0 |
Phosphotyrosine | 17 | 6.0 |
Cell Division/*drug effects | 3 | 1.0 |
Interleukin-1/*pharmacology | 3 | 0.0 |
Mice | 82 | 0.0 |
Mice, SCID | 2 | 0.0 |
Phosphotyrosine/metabolism | 16 | 3.0 |
Protein-Tyrosine Kinase/*metabolism | 99 | 12.0 |
Signal Transduction | 91 | 1.0 |
DNA-Binding Proteins/*metabolism | 56 | 2.0 |
Enzyme Activation/drug effects | 15 | 1.0 |
Interleukin-10/*pharmacology | 4 | 4.0 |
Interleukins/*pharmacology | 4 | 5.0 |
JNK Mitogen-Activated Protein Kinases | 4 | 0.0 |
Mitogen-Activated Protein Kinases/*metabolism | 3 | 0.0 |
Proteins/metabolism | 30 | 3.0 |
*Proto-Oncogene Proteins | 107 | 6.0 |
Rats | 21 | 0.0 |
Signal Transduction/drug effects | 8 | 1.0 |
Trans-Activators/*metabolism | 59 | 6.0 |
Tumor Cells, Cultured | 85 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 4 | 0.0 |
Chromosome Mapping | 6 | 0.0 |
*Chromosomes, Human, Pair 1 | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 15 | 0.0 |
Antibodies, Monoclonal/pharmacology | 2 | 0.0 |
Cell Division/drug effects | 17 | 0.0 |
Cell Nucleus/metabolism | 10 | 0.0 |
DNA-Binding Proteins/metabolism | 58 | 3.0 |
Kinetics | 15 | 0.0 |
Phosphoproteins/metabolism | 13 | 2.0 |
Phosphorylation/drug effects | 17 | 2.0 |
*Signal Transduction | 55 | 2.0 |
Trans-Activators/metabolism | 67 | 7.0 |
Aged | 4 | 0.0 |
Female | 16 | 0.0 |
Cell Division/genetics | 3 | 0.0 |
Cloning, Molecular | 13 | 0.0 |
DNA, Complementary/genetics | 3 | 0.0 |
Gene Expression Regulation/drug effects | 9 | 1.0 |
*Gene Expression Regulation, Neoplastic | 4 | 0.0 |
Mutation | 20 | 0.0 |
Transfection | 61 | 0.0 |
3T3 Cells | 12 | 0.0 |
Enzyme Activation | 57 | 1.0 |
Interferon Type II/metabolism | 4 | 1.0 |
Mitogen-Activated Protein Kinases/metabolism | 7 | 0.0 |
*Protein-Serine-Threonine Kinases | 5 | 0.0 |
Proto-Oncogene Proteins/metabolism | 9 | 0.0 |
Signal Transduction/physiology | 5 | 0.0 |
B-Lymphocytes/*metabolism | 2 | 1.0 |
Blotting, Western | 24 | 0.0 |
Cell Separation | 2 | 0.0 |
Flow Cytometry | 8 | 0.0 |
Interleukin-4/*metabolism | 3 | 7.0 |
Models, Genetic | 2 | 0.0 |
Precipitin Tests | 20 | 0.0 |
RNA, Messenger/metabolism | 7 | 0.0 |
Recombinant Proteins/metabolism | 11 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 9 | 0.0 |
Antigens, CD/physiology | 4 | 1.0 |
Apoptosis | 5 | 0.0 |
Cell Division | 17 | 0.0 |
Cell Survival/drug effects | 6 | 0.0 |
Dose-Response Relationship, Drug | 11 | 0.0 |
Drug Synergism | 3 | 0.0 |
Interleukin-6/physiology | 3 | 4.0 |
Male | 17 | 0.0 |
Membrane Glycoproteins/physiology | 2 | 1.0 |
Middle Aged | 5 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
Apoptosis/drug effects | 3 | 0.0 |
Carrier Proteins/genetics/metabolism | 2 | 1.0 |
Down-Regulation | 7 | 0.0 |
Electrophoretic Mobility Shift Assay | 2 | 0.0 |
Interleukin-6/*pharmacology | 7 | 3.0 |
*Intracellular Signaling Peptides and Proteins | 11 | 1.0 |
Protein Transport | 2 | 0.0 |
*Repressor Proteins | 12 | 1.0 |
Transforming Growth Factor beta/*pharmacology | 3 | 0.0 |
Tumor Cells, Cultured/drug effects/metabolism | 3 | 1.0 |
Tyrosine/metabolism | 42 | 3.0 |
DNA-Binding Proteins/genetics/*metabolism | 10 | 1.0 |
Interferon-alpha/metabolism | 3 | 13.0 |
Interferon-beta/metabolism | 3 | 15.0 |
Trans-Activators/genetics/*metabolism | 11 | 3.0 |
DNA-Binding Proteins/*immunology | 2 | 8.0 |
Disease Models, Animal | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 12 | 0.0 |
Gene Expression | 9 | 0.0 |
Interleukin-2/pharmacology | 11 | 1.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors/*immunology | 2 | 50.0 |
Rabbits | 5 | 0.0 |
Signal Transduction/*immunology | 9 | 2.0 |
Trans-Activators/*immunology | 2 | 16.0 |
Tyrphostins/pharmacology | 6 | 4.0 |
Antigens, CD/metabolism | 10 | 1.0 |
Chick Embryo | 3 | 0.0 |
Cytokines/pharmacology | 5 | 1.0 |
Membrane Glycoproteins/metabolism | 5 | 0.0 |
Neuroblastoma | 2 | 1.0 |
*Signal Transduction/drug effects | 5 | 5.0 |
Interferon Type II/*pharmacology | 16 | 3.0 |
*Nuclear Proteins | 5 | 0.0 |
Receptors, Interferon/biosynthesis | 3 | 60.0 |
Transcription, Genetic | 15 | 0.0 |
*GTP-Binding Proteins | 2 | 3.0 |
Liver/metabolism | 2 | 0.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 5 | 1.0 |
Mitogen-Activated Protein Kinase 3 | 8 | 1.0 |
Protein-Tyrosine-Phosphatase/metabolism | 4 | 3.0 |
Receptors, Interferon/metabolism | 6 | 15.0 |
Reference Values | 2 | 0.0 |
Signal Transduction/*physiology | 21 | 1.0 |
*Transcription Factors | 6 | 0.0 |
eIF-2 Kinase/metabolism | 2 | 14.0 |
Antigens, CD/*metabolism | 4 | 0.0 |
Microscopy, Fluorescence | 4 | 0.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 2 | 0.0 |
DNA-Binding Proteins/metabolism/*physiology | 2 | 1.0 |
Interleukin-6/pharmacology | 5 | 1.0 |
Luciferases/genetics | 3 | 0.0 |
Promoter Regions (Genetics) | 9 | 0.0 |
Protein-Tyrosine Kinase/metabolism/physiology | 2 | 20.0 |
RNA, Messenger/genetics | 5 | 0.0 |
Trans-Activation (Genetics)/*physiology | 2 | 1.0 |
Trans-Activators/metabolism/*physiology | 3 | 5.0 |
COS Cells | 17 | 0.0 |
Hela Cells | 17 | 0.0 |
Receptors, Cytokine/*metabolism | 5 | 5.0 |
Up-Regulation | 6 | 0.0 |
Cell Adhesion | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Genes, Dominant | 3 | 0.0 |
Intercellular Adhesion Molecule-1/*biosynthesis | 2 | 4.0 |
Isoenzymes/metabolism | 2 | 0.0 |
Luciferases/metabolism | 3 | 0.0 |
Plasmids/metabolism | 6 | 0.0 |
Time Factors | 16 | 0.0 |
U937 Cells | 2 | 0.0 |
src-Family Kinases/metabolism | 5 | 2.0 |
*Adaptor Proteins, Signal Transducing | 10 | 0.0 |
Carrier Proteins/*metabolism | 2 | 0.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
Protein Binding | 28 | 0.0 |
Comparative Study | 26 | 0.0 |
Enzyme Activation/immunology | 6 | 4.0 |
Histocompatibility Antigens Class I/biosynthesis | 2 | 4.0 |
Interferon Type II/antagonists & inhibitors/biosynthesis | 2 | 22.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Mice, Knockout | 6 | 0.0 |
Milk Proteins/metabolism | 2 | 18.0 |
Signal Transduction/genetics/*immunology | 2 | 2.0 |
*Cell Cycle Proteins | 3 | 0.0 |
Cell Line, Transformed | 14 | 0.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors/metabolism/*physiology | 2 | 16.0 |
Acute Disease | 2 | 0.0 |
Alternative Splicing | 2 | 0.0 |
Dimerization | 15 | 1.0 |
Protein Processing, Post-Translational | 10 | 1.0 |
Signal Transduction/genetics | 3 | 1.0 |
Growth Inhibitors/pharmacology | 3 | 2.0 |
Interferon-beta/pharmacology | 4 | 8.0 |
Protein Biosynthesis | 4 | 0.0 |
Proteins/genetics | 8 | 1.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Amino Acid Sequence | 46 | 0.0 |
Molecular Sequence Data | 79 | 0.0 |
Protein-Tyrosine Kinase/chemistry/*metabolism | 3 | 8.0 |
Protein-Tyrosine-Phosphatase/*metabolism | 6 | 4.0 |
Sequence Homology, Amino Acid | 17 | 0.0 |
Substrate Specificity | 6 | 0.0 |
Cell Survival | 6 | 0.0 |
Ligands | 5 | 0.0 |
Proteins/*metabolism | 10 | 1.0 |
Receptors, Erythropoietin/metabolism | 2 | 6.0 |
Receptors, Interleukin/metabolism | 7 | 12.0 |
Glutathione Transferase/metabolism | 3 | 0.0 |
K562 Cells | 2 | 0.0 |
Tyrosine/*metabolism | 8 | 2.0 |
1-Phosphatidylinositol 3-Kinase/*metabolism | 2 | 0.0 |
*Apoptosis | 2 | 0.0 |
MAP Kinase Kinase 1 | 3 | 1.0 |
Phosphoproteins/*metabolism | 9 | 1.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors | 2 | 2.0 |
Proto-Oncogene Proteins | 2 | 5.0 |
Binding Sites | 13 | 0.0 |
Cytoplasm/metabolism | 4 | 0.0 |
Fibrosarcoma | 4 | 8.0 |
Membrane Glycoproteins/*metabolism | 3 | 0.0 |
Protein-Tyrosine Kinase/genetics/*metabolism | 7 | 5.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Base Sequence | 60 | 0.0 |
Tissue Distribution | 4 | 0.0 |
Trans-Activation (Genetics) | 6 | 0.0 |
*Adaptor Proteins, Vesicular Transport | 3 | 1.0 |
*Trans-Activation (Genetics) | 2 | 0.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Protein-Tyrosine Kinase/physiology | 7 | 5.0 |
Signal Transduction/drug effects/physiology | 3 | 1.0 |
Solubility | 2 | 0.0 |
Cell Culture Techniques | 2 | 0.0 |
Receptors, Interleukin-2/metabolism | 5 | 2.0 |
Trans-Activation (Genetics)/drug effects | 2 | 0.0 |
Blotting, Northern | 7 | 0.0 |
Genes, fos | 3 | 2.0 |
MAP Kinase Signaling System/drug effects | 4 | 4.0 |
Macromolecular Substances | 13 | 0.0 |
Proto-Oncogene Proteins c-fos/biosynthesis | 2 | 6.0 |
Receptors, Cytokine/physiology | 3 | 11.0 |
Signal Transduction/*drug effects | 20 | 5.0 |
Adult | 8 | 0.0 |
DNA-Binding Proteins/analysis | 2 | 2.0 |
Protein-Tyrosine Kinase/*analysis | 2 | 6.0 |
Trans-Activators/*analysis | 2 | 8.0 |
DNA-Binding Proteins/*physiology | 6 | 1.0 |
Interferons/*pharmacology | 3 | 4.0 |
Receptors, Interferon/physiology | 2 | 28.0 |
Trans-Activators/*physiology | 7 | 2.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 5 | 0.0 |
Cell Adhesion Molecules/*metabolism | 2 | 0.0 |
Cytoskeletal Proteins/metabolism | 2 | 0.0 |
Hematopoietic Stem Cells/*physiology | 2 | 1.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Phosphotyrosine/*metabolism | 3 | 4.0 |
Biopsy | 2 | 0.0 |
Disease Progression | 2 | 0.0 |
RNA, Messenger/analysis | 7 | 0.0 |
Drug Evaluation, Preclinical | 2 | 1.0 |
MAP Kinase Signaling System | 2 | 0.0 |
DNA/metabolism | 12 | 0.0 |
Enzyme Inhibitors/*pharmacology | 3 | 0.0 |
Immunoblotting | 5 | 0.0 |
Interferon-alpha/*metabolism | 5 | 21.0 |
Jurkat Cells | 4 | 0.0 |
Ribonucleases/metabolism | 2 | 1.0 |
English Abstract | 4 | 0.0 |
Interleukin-6/*physiology | 3 | 3.0 |
Multiple Myeloma/pathology/*physiopathology | 2 | 100.0 |
*Gene Expression Regulation, Viral | 2 | 0.0 |
Catalysis | 3 | 0.0 |
Cell Line, Tumor | 4 | 0.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Immunohistochemistry | 7 | 0.0 |
Immunoprecipitation | 2 | 0.0 |
*Mutation | 2 | 0.0 |
Protein Conformation | 4 | 0.0 |
Tyrosine/chemistry | 3 | 2.0 |
Fluorescent Antibody Technique | 4 | 0.0 |
Interstitial Collagenase/metabolism | 2 | 8.0 |
Antineoplastic Agents/*pharmacology | 6 | 0.0 |
DNA/genetics | 2 | 0.0 |
Interferon-alpha/*pharmacology | 14 | 10.0 |
Epithelium, Corneal/cytology/*drug effects/metabolism | 2 | 40.0 |
Genistein/pharmacology | 2 | 1.0 |
Interferon-gamma, Recombinant/*pharmacology | 4 | 3.0 |
Molecular Weight | 4 | 0.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors/metabolism | 4 | 9.0 |
Interferon-alpha/pharmacology | 5 | 5.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors/metabolism | 2 | 2.0 |
Interleukin-4/*physiology | 5 | 10.0 |
Lymphocyte Activation/genetics | 2 | 2.0 |
Mutagenesis, Site-Directed | 12 | 0.0 |
Receptor, Insulin/*metabolism | 2 | 3.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Gene Expression Regulation/*drug effects | 6 | 0.0 |
Gene Expression/drug effects | 4 | 0.0 |
Interleukin-2/*physiology | 3 | 4.0 |
RNA, Messenger/drug effects/metabolism | 2 | 1.0 |
Transcription, Genetic/drug effects | 4 | 0.0 |
Cysteine Endopeptidases/*metabolism | 2 | 0.0 |
DNA/genetics/metabolism | 4 | 1.0 |
DNA-Binding Proteins/*antagonists & inhibitors/metabolism | 2 | 6.0 |
Interleukin-6/*antagonists & inhibitors/pharmacology | 2 | 33.0 |
Leupeptins/pharmacology | 2 | 1.0 |
Models, Biological | 12 | 0.0 |
Mutation/genetics | 2 | 0.0 |
Proteasome Endopeptidase Complex | 2 | 0.0 |
Trans-Activators/*antagonists & inhibitors/metabolism | 2 | 10.0 |
Genes, Reporter | 5 | 0.0 |
Multigene Family | 2 | 0.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Liver/*metabolism | 3 | 0.0 |
Protein-Tyrosine Kinase/genetics | 2 | 1.0 |
Trans-Activators/genetics | 2 | 0.0 |
Cell Division/drug effects/physiology | 2 | 0.0 |
Lymphokines/pharmacology | 4 | 2.0 |
Neoplasm Proteins/metabolism | 3 | 0.0 |
Peptides/*pharmacology | 6 | 2.0 |
Amino Acid Substitution | 2 | 0.0 |
Carrier Proteins/*pharmacology | 2 | 4.0 |
Interferon Type II/*antagonists & inhibitors/pharmacology | 2 | 66.0 |
Protein Processing, Post-Translational/*drug effects | 4 | 7.0 |
Receptors, Interleukin-6/physiology | 2 | 22.0 |
Regulatory Sequences, Nucleic Acid | 4 | 0.0 |
Biological Transport/drug effects | 2 | 0.0 |
DNA-Binding Proteins/chemistry/*metabolism | 3 | 1.0 |
Interferons/pharmacology | 3 | 4.0 |
Models, Molecular | 4 | 0.0 |
Recombinant Fusion Proteins/metabolism | 10 | 0.0 |
Vanadates/pharmacology | 3 | 2.0 |
Flavonoids/pharmacology | 2 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 3 | 0.0 |
Interleukin-5/*pharmacology | 2 | 6.0 |
*Proto-Oncogene Proteins c-bcl-2 | 2 | 0.0 |
Structure-Activity Relationship | 10 | 0.0 |
*src Homology Domains | 3 | 1.0 |
Exons | 3 | 0.0 |
Gene Expression Regulation | 10 | 0.0 |
Introns | 3 | 0.0 |
Phylogeny | 4 | 0.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Protein-Tyrosine Kinase/*genetics | 6 | 2.0 |
Sequence Alignment | 5 | 0.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Depression, Chemical | 2 | 1.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors | 4 | 2.0 |
CHO Cells | 10 | 0.0 |
Hamsters | 11 | 0.0 |
Protein Synthesis Inhibitors/pharmacology | 2 | 0.0 |
*Protein Processing, Post-Translational | 5 | 1.0 |
Protein-Tyrosine-Phosphatase/*physiology | 2 | 7.0 |
Receptors, Interleukin-2/drug effects/*metabolism | 2 | 40.0 |
Cell Division/physiology | 4 | 0.0 |
Interleukin-4/*pharmacology | 12 | 5.0 |
src Homology Domains | 9 | 1.0 |
Cell Proliferation/drug effects | 2 | 2.0 |
Tretinoin/*pharmacology | 2 | 0.0 |
Growth Inhibitors/*pharmacology | 2 | 1.0 |
Recombinant Proteins/pharmacology | 10 | 0.0 |
Carcinoma, Hepatocellular/metabolism | 2 | 2.0 |
Insulin/*pharmacology | 2 | 0.0 |
Protein-Tyrosine Kinase/*physiology | 9 | 6.0 |
*Transcription, Genetic | 5 | 0.0 |
Dexamethasone/pharmacology | 3 | 0.0 |
Stimulation, Chemical | 2 | 0.0 |
Cricetulus | 2 | 0.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
Receptors, Interferon/*metabolism | 3 | 10.0 |
Serine/metabolism | 2 | 0.0 |
Forskolin/pharmacology | 2 | 0.0 |
Interferon-gamma, Recombinant/pharmacology | 7 | 4.0 |
*Protein Biosynthesis | 4 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 6 | 0.0 |
Cytokines/metabolism | 2 | 0.0 |
Interleukin-3/metabolism | 2 | 6.0 |
Transcription Factors/chemistry/*metabolism | 2 | 1.0 |
DNA-Binding Proteins/analysis/metabolism | 2 | 9.0 |
Protein-Tyrosine Kinase/analysis/metabolism | 2 | 33.0 |
Proteins/analysis/metabolism | 2 | 33.0 |
Trans-Activators/analysis/metabolism | 2 | 50.0 |
Hematopoietic Stem Cells/cytology/physiology | 2 | 13.0 |
Genes, MHC Class II | 2 | 0.0 |
CCAAT-Enhancer-Binding Proteins | 2 | 1.0 |
Oligodeoxyribonucleotides | 5 | 0.0 |
Transcription Factors/metabolism | 11 | 0.0 |
DNA Primers | 4 | 0.0 |
DNA-Binding Proteins/biosynthesis/*metabolism | 2 | 3.0 |
Trans-Activators/biosynthesis/*metabolism | 2 | 13.0 |
*Gene Expression Profiling | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis | 5 | 0.0 |
Response Elements | 2 | 0.0 |
Viral Proteins/*pharmacology | 2 | 11.0 |
Isoenzymes/*metabolism | 2 | 0.0 |
Neoplasm Proteins/*metabolism | 2 | 0.0 |
Receptor Protein-Tyrosine Kinases/metabolism | 2 | 0.0 |
Cell Transformation, Viral | 2 | 0.0 |
*Lymphocyte Activation | 3 | 0.0 |
Protein-Tyrosine Kinase/analysis/*metabolism | 3 | 42.0 |
Interferon Type I, Recombinant/pharmacology | 2 | 6.0 |
Phosphoproteins/chemistry/*metabolism | 2 | 3.0 |
Interferon Type II/*physiology | 6 | 9.0 |
Lipopolysaccharides/*pharmacology | 2 | 0.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors/metabolism | 2 | 3.0 |
Polymerase Chain Reaction | 7 | 0.0 |
Interleukin-4/pharmacology | 9 | 2.0 |
Receptors, Interleukin-2/chemistry/genetics/*metabolism | 2 | 66.0 |
*Mitogen-Activated Protein Kinases | 5 | 1.0 |
Signal Transduction/immunology | 5 | 1.0 |
Binding Sites/drug effects | 2 | 3.0 |
Computer Simulation | 2 | 0.0 |
Drug Design | 3 | 0.0 |
Quinazolines/*pharmacology | 2 | 2.0 |
Cytokines/physiology | 2 | 1.0 |
Molecular Structure | 2 | 0.0 |
Recombinant Fusion Proteins/genetics | 2 | 1.0 |
Protein-Tyrosine Kinase/genetics/metabolism | 2 | 2.0 |
Proteins/genetics/*metabolism | 4 | 0.0 |
Interleukins/metabolism | 2 | 6.0 |
Interleukin-3/pharmacology | 4 | 1.0 |
Adolescent | 2 | 0.0 |
Alleles | 3 | 0.0 |
Child | 3 | 0.0 |
DNA-Binding Proteins/immunology | 2 | 9.0 |
Trans-Activators/immunology | 2 | 14.0 |
DNA Primers/genetics | 4 | 0.0 |
Fibroblasts | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Gene Library | 4 | 0.0 |
*Immune Tolerance | 3 | 1.0 |
Receptors, Interleukin-2/*metabolism | 6 | 8.0 |
Receptor, Epidermal Growth Factor/metabolism | 2 | 0.0 |
Adenylate Cyclase/metabolism | 2 | 1.0 |
T-Lymphocytes/*drug effects/enzymology | 3 | 30.0 |
Cell Differentiation | 5 | 0.0 |
HL-60 Cells | 3 | 0.0 |
Chimeric Proteins/metabolism | 3 | 1.0 |
Protein-Tyrosine Kinase/*genetics/metabolism | 4 | 8.0 |
Interferon Type II/*metabolism | 2 | 3.0 |
In Vitro | 4 | 0.0 |
Receptors, Interleukin-2/chemistry/metabolism | 2 | 33.0 |
Receptors, Interleukin/*physiology | 4 | 16.0 |
Macrophages/cytology/*physiology | 2 | 15.0 |
Protein-Tyrosine-Phosphatase/genetics/*metabolism | 2 | 4.0 |
Receptors, Cytokine/metabolism | 5 | 5.0 |
Enzyme Induction | 2 | 0.0 |
Interleukin-13/*pharmacology/physiology | 2 | 40.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Antigens, CD/chemistry/*physiology | 2 | 14.0 |
Chimeric Proteins/chemistry/metabolism | 2 | 3.0 |
Interleukin-6/pharmacology/*physiology | 2 | 18.0 |
Membrane Glycoproteins/chemistry/*physiology | 2 | 13.0 |
Conserved Sequence | 3 | 0.0 |
Mice, Inbred BALB C | 4 | 0.0 |
Point Mutation | 4 | 0.0 |
Recombinant Fusion Proteins/biosynthesis | 3 | 0.0 |
Sequence Deletion | 2 | 0.0 |
DNA-Binding Proteins/physiology | 4 | 1.0 |
Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Trans-Activators/physiology | 5 | 3.0 |
src Homology Domains/physiology | 2 | 4.0 |
Interleukin-2/physiology | 2 | 2.0 |
Receptors, Interferon/chemistry/genetics/*metabolism | 3 | 37.0 |
Cross-Linking Reagents | 2 | 0.0 |
Receptors, Interleukin/genetics/*metabolism | 2 | 25.0 |
Acute-Phase Proteins/metabolism | 2 | 3.0 |
Antibodies, Monoclonal | 3 | 0.0 |
Growth Substances/*pharmacology | 2 | 0.0 |
Receptors, Interleukin/*chemistry | 2 | 28.0 |
Apoptosis/*physiology | 2 | 0.0 |
Lymphocyte Activation/*physiology | 2 | 2.0 |
*Protein-Tyrosine Kinase | 2 | 0.0 |
Proteins/*physiology | 3 | 1.0 |
Interleukin-2/metabolism | 2 | 1.0 |
Cyclic AMP-Dependent Protein Kinases/*metabolism | 2 | 2.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 4 | 1.0 |
Cell Differentiation/physiology | 2 | 0.0 |
Signal Transduction/drug effects/*physiology | 3 | 1.0 |
Interleukin-2/*immunology | 2 | 3.0 |
Antigens, CD/genetics/*metabolism | 2 | 2.0 |
Interleukin-11/*pharmacology | 2 | 12.0 |
Receptors, Interleukin/*metabolism | 3 | 9.0 |
Genes, Reporter/genetics | 2 | 0.0 |
Receptor Protein-Tyrosine Kinases/*metabolism | 3 | 1.0 |
Chickens | 2 | 0.0 |
src-Family Kinases/*metabolism | 2 | 1.0 |
Recombinant Proteins/metabolism/pharmacology | 4 | 3.0 |
*Gene Expression Regulation | 4 | 0.0 |
Interleukin-2/*metabolism | 2 | 4.0 |
Erythropoietin/pharmacology | 3 | 2.0 |
Prolactin/pharmacology | 2 | 5.0 |
Proto-Oncogene Proteins/*metabolism | 3 | 0.0 |
Receptors, Cell Surface/*metabolism | 2 | 0.0 |
DNA, Complementary | 4 | 0.0 |
Cytosol/metabolism | 2 | 0.0 |
Interferon Type II/pharmacology | 11 | 1.0 |
Recombinant Fusion Proteins/chemistry/genetics/metabolism | 2 | 1.0 |
Rats, Wistar | 2 | 0.0 |
Granulocyte Colony-Stimulating Factor/*pharmacology | 4 | 3.0 |
Receptors, Granulocyte Colony-Stimulating Factor/biosynthesis/*physiology | 2 | 100.0 |
1-Phosphatidylinositol 3-Kinase | 6 | 4.0 |
Cell Division/immunology | 2 | 0.0 |
T-Lymphocytes/*immunology | 3 | 0.0 |
Antigens, CD/immunology | 2 | 0.0 |
Monocytes/*metabolism | 2 | 0.0 |
Receptors, IgG/*biosynthesis/genetics | 2 | 50.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Receptors, Interleukin-4 | 12 | 17.0 |
Receptors, Interleukin-6 | 3 | 3.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Receptors, Interleukin-7 | 4 | 23.0 |
Recombinant Proteins/biosynthesis/pharmacology | 3 | 10.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 2 | 0.0 |
Epidermal Growth Factor/pharmacology | 2 | 0.0 |
Interferon-beta/*pharmacology | 5 | 8.0 |
*Mitogen-Activated Protein Kinase Kinases | 2 | 2.0 |
*Interleukin-6 | 2 | 0.0 |
Receptors, Interferon/chemistry/genetics/*physiology | 2 | 100.0 |
Phosphotransferases (Alcohol Group Acceptor)/*metabolism | 4 | 4.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 4 | 1.0 |
Interleukin-2/pharmacology/*physiology | 2 | 28.0 |
Receptors, Interleukin/physiology | 3 | 20.0 |
B-Lymphocytes/*immunology/metabolism | 2 | 4.0 |
T-Lymphocytes | 2 | 0.0 |
B-Lymphocytes/*immunology | 3 | 0.0 |
Receptors, Interleukin/immunology | 2 | 16.0 |
Fibrosarcoma/metabolism | 2 | 16.0 |
Chimeric Proteins | 2 | 2.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 2 | 0.0 |
Interleukin-13/*pharmacology | 4 | 8.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
Herpesvirus 4, Human | 3 | 2.0 |
Signal Transduction/*drug effects/genetics | 2 | 20.0 |
Receptors, Somatotropin/metabolism | 3 | 13.0 |
Mammals | 2 | 0.0 |
Cytoplasm | 2 | 3.0 |
Receptor Aggregation | 2 | 2.0 |
Interleukin-4/metabolism | 2 | 2.0 |
Electrophoresis, Polyacrylamide Gel | 4 | 0.0 |
Interferon-alpha/physiology | 2 | 25.0 |
Interleukin-7/*pharmacology | 2 | 4.0 |
Thymidine/metabolism | 2 | 0.0 |
Interleukin-12/*pharmacology | 2 | 4.0 |
Protein-Tyrosine Kinase/biosynthesis/*metabolism | 2 | 18.0 |
Protein-Tyrosine Kinase/metabolism/*physiology | 3 | 11.0 |
Growth Hormone/*pharmacology | 4 | 5.0 |
Epidermal Growth Factor/*pharmacology | 2 | 0.0 |
Transcription Factors/*metabolism | 6 | 0.0 |
Tyrosine | 2 | 1.0 |
B-Lymphocytes/drug effects/*metabolism/pathology | 2 | 100.0 |
*Gene Therapy | 2 | 0.0 |
Genetic Complementation Test | 4 | 0.0 |
Genetic Vectors/*genetics | 2 | 2.0 |
Retroviridae/*genetics | 2 | 1.0 |
Severe Combined Immunodeficiency/genetics/pathology/*therapy | 2 | 66.0 |
X Chromosome/genetics | 2 | 1.0 |
Luciferases/biosynthesis | 2 | 2.0 |
Sheep | 2 | 0.0 |
Phosphoproteins/isolation & purification/metabolism | 2 | 5.0 |
*Cell Transformation, Neoplastic | 2 | 0.0 |
Hematopoietic Stem Cells | 3 | 4.0 |
Protein-Tyrosine Kinase/*biosynthesis | 3 | 12.0 |
Vanadates/*pharmacology | 2 | 8.0 |
Oligodeoxyribonucleotides/chemistry | 2 | 0.0 |
*Antigens, CD | 3 | 0.0 |
Phospholipase C/*metabolism | 2 | 1.0 |
Models, Structural | 2 | 1.0 |
Receptor, Epidermal Growth Factor/*metabolism | 2 | 0.0 |
T-Lymphocytes/*metabolism | 4 | 1.0 |
Transcription Factors/biosynthesis | 2 | 2.0 |
Interleukin-3/*pharmacology | 2 | 1.0 |
*Neoplasm Proteins | 2 | 0.0 |
Recombinant Proteins/biosynthesis/metabolism/pharmacology | 2 | 16.0 |
Hybrid Cells | 3 | 0.0 |
Peptide Mapping | 2 | 0.0 |
Interleukin-9/*pharmacology | 2 | 25.0 |
Tyrosine/analogs & derivatives/analysis | 2 | 5.0 |
DNA | 2 | 0.0 |
Tyrosine/analogs & derivatives/metabolism | 8 | 6.0 |
Cytokines/*pharmacology | 3 | 0.0 |
Blotting, Southern | 2 | 0.0 |
Receptors, Interleukin-2/chemistry/*metabolism | 2 | 28.0 |
Receptor, erbB-2/metabolism | 2 | 1.0 |
Mutagenesis | 3 | 0.0 |
Receptors, Cytokine/*physiology | 2 | 7.0 |
Promoter Regions (Genetics)/drug effects | 2 | 1.0 |
Receptors, Interleukin-2/genetics/*metabolism | 2 | 28.0 |
Protein Binding/drug effects | 2 | 0.0 |
Tyrosine/*analogs & derivatives/analysis/metabolism | 2 | 22.0 |
Gene Expression Profiling | 2 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Protein Kinases/*genetics/metabolism | 2 | 8.0 |
Immunoblotting/methods | 2 | 4.0 |
Pyrimidines/*pharmacology | 2 | 3.0 |
Collagen Type II/*genetics | 2 | 9.0 |
